You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國生物製藥(01177.HK):新型口服抗凝藥物"阿哌沙班片"獲藥品註冊證書
格隆匯 07-30 17:34

格隆匯 7 月 30日丨中國生物製藥(01177.HK)宣佈,集團開發的新型口服抗凝藥物"阿哌沙班片"(商標名:艾瑞通)已獲得中華人民共和國國家藥品監督管理局頒發藥品註冊證書,且視同通過仿製藥質量和療效一致性評價。

阿哌沙班是一種高選擇性的凝血因子Xa抑制劑,適用於預防靜脈血栓栓塞事件發生,降低中風和全身性栓塞風險。相比傳統抗凝血藥,阿哌沙班療效確切且安全性更好,無需常規凝血監測,無需複雜的劑量調整,用藥更加方便。靜脈血栓栓塞症是繼心肌梗死和卒中後,造成心血管疾病相關死亡的第三大原因。艾瑞通獲批上市,將有助於快速提高國內新型口服抗凝藥的普及率,提升心血管疾病防治水平。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account